Thus, this study addresses a direct clinical need in a disease difficult to treat, and documents preclinical proof of concept of the positive impact that CCR9-directed immunotherapy can have on the treatment of T-ALL and other CCR9 expressing malignancies. The gene discussed is CCR9; the disease is acute lymphoblastic leukemia.